Suppr超能文献

改性外泌体:干细胞内 miRNA 的良好载体,可用于治疗缺血性心脏病。

Modified Exosomes: a Good Transporter for miRNAs within Stem Cells to Treat Ischemic Heart Disease.

机构信息

NHC Key Laboratory of Assisted Circulation, Sun Yat-Sen University, Guangzhou, China.

National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

出版信息

J Cardiovasc Transl Res. 2022 Jun;15(3):514-523. doi: 10.1007/s12265-022-10216-1. Epub 2022 Feb 28.

Abstract

Stem cell-based therapy for ischemic heart disease (IHD) has become a promising but controversial strategy during the past two decades. The fate and effects of stem cells engrafted into ischemia myocardium are still not fully understood. Stem cell-derived exosomes, a subcategory of extracellular vesicles with nano size, have been considered as an efficient and safe transporter for microRNAs (miRNAs) and a central mediator of the cardioprotective potentials of the parental cells. Hypoxia, pharmacological intervention, and gene manipulation could alter the exosomal miRNAs cargos from stem cells and promote therapeutic potential. Furthermore, several bioengineering methods were also successfully applied to modify miRNAs content and components of exosomal membrane proteins recently. In this review, we outline relevant results about exosomal miRNAs from stem cells and focus on the current strategies to promote their therapeutic efficiency in IHD.

摘要

在过去的二十年中,基于干细胞的治疗缺血性心脏病(IHD)已成为一种有前途但有争议的策略。植入缺血心肌的干细胞的命运和影响仍不完全清楚。干细胞衍生的外泌体是纳米大小的细胞外囊泡的一个亚类,被认为是 microRNAs(miRNAs)的有效和安全的转运体,也是亲本细胞的心脏保护潜力的中心介质。缺氧、药物干预和基因操作可以改变干细胞来源的外泌体中的 miRNA 货物,并促进治疗潜力。此外,最近还成功应用了几种生物工程方法来修饰外泌体膜蛋白的 miRNA 含量和成分。在这篇综述中,我们概述了干细胞来源的外泌体 miRNA 的相关结果,并重点介绍了提高其在 IHD 治疗效率的当前策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验